NCT01601626: Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV |
|
|
| Terminated | 2b | 71 | RoW | Standard-dose Lopinavir/Ritonavir, LPV/RTV, LPV/r, Aluvia, Kaletra, Double-dose Lopinavir/Ritonavir, Raltegravir, RAL, Isentress, Isoniazid, INH, Pyridoxine, Vitamin B6, Pyrazinamide, PZA, Ethambutol, EMB, Rifabutin, RBT, Rifampin, RIF | AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infection, Tuberculosis | 01/17 | 06/17 | | |
NCT00640887: Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa |
|
|
| Completed | 2 | 48 | RoW | rifabutin in combination with efavirenz, rifabutin in combination with nevirapine, rifabutin in combination with lopinavir/ritonavir | French National Agency for Research on AIDS and Viral Hepatitis | HIV Infections, Tuberculosis | 10/10 | 10/10 | | |
